Bayer AG
XETRA:BAYN
Bayer AG
XETRA:BAYN
Price:
28.32 EUR
0.68%
Updated:
May 3, 2024
Bayer AG
Cash Equivalents
|
Bayer AG
Cash Equivalents Peer Comparison
Comparables:
ATAI
MRK
93M1
DMP
PSG
Competitive Cash Equivalents Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Bayer AG
XETRA:BAYN
|
Cash Equivalents
€5.9B
|
CAGR 3-Years
12%
|
CAGR 5-Years
8%
|
CAGR 10-Years
14%
|
|
|
ATAI Life Sciences NV
NASDAQ:ATAI
|
Cash Equivalents
$45m
|
CAGR 3-Years
-23%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Merck KGaA
XETRA:MRK
|
Cash Equivalents
€2B
|
CAGR 3-Years
14%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
7%
|
|
|
MPH Health Care AG
XETRA:93M1
|
Cash Equivalents
€1.8m
|
CAGR 3-Years
1%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Dermapharm Holding SE
XETRA:DMP
|
Cash Equivalents
€158.7m
|
CAGR 3-Years
10%
|
CAGR 5-Years
14%
|
CAGR 10-Years
N/A
|
|
|
PharmaSGP Holding SE
XETRA:PSG
|
Cash Equivalents
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is Bayer AG's Cash Equivalents?
Cash Equivalents
5.9B
EUR
5.9B
EUR
Based on the financial report for Dec 31, 2023, Bayer AG's Cash Equivalents amounts to 5.9B EUR.
What is Bayer AG's Cash Equivalents growth rate?
Cash Equivalents CAGR 10Y
14%
14%
Over the last year, the Cash Equivalents growth was 14%. The average annual Cash Equivalents growth rates for Bayer AG have been 12% over the past three years , 8% over the past five years , and 14% over the past ten years .
You don't have any saved screeners yet
